First Immunotherapy Treatment Approved for Stage III

2018-03-21T16:24:45+00:00February 16th, 2018|Hot Topics, News|0 Comments

Friday, February 16, 2018. Today the Food and Drug Administration (FDA) approved Imfinzi (durvalumab), the first immunotherapy drug for stage III non-small cell lung cancer. This approval is what is called “maintenance” therapy, which is when you take a drug to help prevent cancer from growing or coming back following earlier treatment protocols. Learn more now.

Leave A Comment

No announcement available or all announcement expired.